GB2507104A — Electronic inhalation device
Assigned to Nicoventures Holdings Ltd · Expires 2014-04-23 · 12y expired
What this patent protects
An electronic inhalation device comprises a mouthpiece 2 and a control unit 24, the control unit 24 comprising a power cell 22 and a computer 20, where the computer 20 comprises a computer processor, a memory and an input-output means; wherein the device further comprises a trans…
USPTO Abstract
An electronic inhalation device comprises a mouthpiece 2 and a control unit 24, the control unit 24 comprising a power cell 22 and a computer 20, where the computer 20 comprises a computer processor, a memory and an input-output means; wherein the device further comprises a transmitter 18 connected to the computer 20 and the computer is configured in use to collect and store use data relating to a user's use of the device in the computer memory and transmit the use data. Preferably, the use data is transmitted wirelessly to a receiver, which may be provided on a smart phone for example. The transmitter preferably comprises audio signalling means and transmits the use data by sound. The receiver may then be provided as a microphone which picks up the sound signal, preferably transmitted at a frequency to avoid background noise.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.